CML CD34+ cells were treated with RITA, CPI-203, the combination thereof and nilotinib.. Treatment of CML cells with RITA, CPI-203, the combination thereof and nilotinib.

NIAID Data Ecosystem2026-03-09 收录

CML药物组合分子机制

白血病靶向治疗研究

数据链接：

https://www.ncbi.nlm.nih.gov/bioproject/PRJEB9942 数据链接链接失效反馈

官方服务：

资源简介：

To identify the molecular effects of combining the p53 activator RITA and MYC inhibitor CPI-203, we treated CML CD34+ cells with RITA, CPI-203, the combination thereof and nilotinib.

创建时间：

2016-05-25

CML CD34+ cells were treated with RITA, CPI-203, the combination thereof and nilotinib.. Treatment of CML cells with RITA, CPI-203, the combination thereof and nilotinib.

资源简介：

相关数据集